Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver

Treatment of acromegaly by rosiglitazone via upregulating 15-PGDH in both pituitary adenoma and liver

Summary: Rosiglitazone, a synthetic peroxisome proliferator-activated receptor γ (PPARγ) ligand, has been reported to reduce growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in 10 patients with acromegaly. However, the mechanisms remain unknown. Here, we reveal that PPARγ directly enhanc...

Full description

Bibliographic Details
Main Authors: Yichao Zhang, Meng Wang, Chenxing Ji, Zhengyuan Chen, Hui Yang, Lei Wang, Yifei Yu, Nidan Qiao, Zengyi Ma, Zhao Ye, Xiaoqing Shao, Wenjuan Liu, Yi Wang, Wei Gong, Vladimir Melnikov, Lydia Hu, Eun Jig Lee, Hongying Ye, Yongfei Wang, Yiming Li, Min He, Yao Zhao, Zhaoyun Zhang
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:iScience
Subjects:
Medicine
Human specimen
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004221009512

Internet

http://www.sciencedirect.com/science/article/pii/S2589004221009512

Similar Items